Intra‐abdominal desmoplastic small round cell tumor: The European pediatric Soft tissue sarcoma Study Group (EpSSG) experience

医学 促结缔组织增生性小圆细胞瘤 肉瘤 软组织肉瘤 软组织 病理
作者
Pablo Berlanga,Daniel Orbach,Reineke A. Schoot,Michela Casanova,Rita Alaggio,Nadège Corradini,Bernadette Brennan,Gema Ramírez,Lisa Lyngsie Hjalgrim,Julia Chisholm,Gianni Bisogno,Beatrice Coppadoro,Akmal Safwat,Johannes H. M. Merks,Gabriela Guillén,Max M. van Noesel,Andrea Ferrari
出处
期刊:Pediatric Blood & Cancer [Wiley]
卷期号:70 (9)
标识
DOI:10.1002/pbc.30447
摘要

This study describes the clinical findings of a consecutive series of pediatric and adolescent patients with a diagnosis of intra-abdominal desmoplastic small round cell tumor (DSRCT) prospectively enrolled in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols: the BERNIE study, the EpSSG MTS 2008 study, and the EpSSG NRSTS 2005 study.Patients aged less than 21 years with a diagnosis of DSRCT arising in the abdomen were included. All trials recommended a multimodal approach including intensive multidrug chemotherapy and loco-regional treatment with surgery and/or radiotherapy whenever possible.The analysis included 32 cases (median age 13.7 years, male:female ratio 1.5:1). Three patients had localized tumors, seven had regionally disseminated disease, and 22 extraperitoneal metastases. All but one patient received multidrug chemotherapy and 11 had maintenance chemotherapy. Loco-regional treatment consisted of surgery only in seven cases, surgery plus adjuvant radiotherapy in 10, and radiotherapy only in six. Among the 17 cases who had radiotherapy, six had irradiation of the primary site, 10 had whole abdominopelvic radiotherapy plus boost to macroscopic residual disease, and one had irradiation to lung metastases only. With a median follow-up of 76 months (range: 18-124 months), 5-year event-free and overall survivals were 19.7% and 21.0%, respectively. Event-free survival was significantly worse for patients who did not receive loco-regional treatment (p-value .007).The study confirmed that the outcome of patients with DSRCT remains dismal and did not improve over recent years despite an intensive multimodal treatment approach.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
狗蛋发布了新的文献求助10
1秒前
彩色大碗发布了新的文献求助20
1秒前
又甘又刻完成签到,获得积分10
1秒前
zoe发布了新的文献求助10
1秒前
快乐小鸟完成签到 ,获得积分10
2秒前
amy完成签到,获得积分0
2秒前
2秒前
3秒前
顺心凝海完成签到,获得积分10
4秒前
852应助zz采纳,获得10
4秒前
kll发布了新的文献求助10
4秒前
guoguo完成签到,获得积分10
5秒前
123发布了新的文献求助10
5秒前
飞于云层之上完成签到,获得积分10
6秒前
王晴晴完成签到,获得积分10
6秒前
6秒前
李健应助吕凯迪采纳,获得10
7秒前
漏漏漏完成签到,获得积分10
7秒前
清爽白梦发布了新的文献求助10
8秒前
文艺香菇完成签到,获得积分20
8秒前
Louuuue完成签到,获得积分10
9秒前
帅哥完成签到,获得积分10
9秒前
星星完成签到,获得积分10
10秒前
在水一方应助漏漏漏采纳,获得10
10秒前
划水火大王完成签到,获得积分10
11秒前
11秒前
11秒前
帅帅的女人完成签到,获得积分20
14秒前
七栀发布了新的文献求助10
15秒前
阿庆完成签到,获得积分10
15秒前
16秒前
顾矜应助娇气的背包采纳,获得10
16秒前
Lucy123关注了科研通微信公众号
17秒前
无头骑士发布了新的文献求助10
17秒前
18秒前
18秒前
19秒前
吕凯迪发布了新的文献求助10
21秒前
22秒前
SciGPT应助kkkkpoa采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6018806
求助须知:如何正确求助?哪些是违规求助? 7609979
关于积分的说明 16160469
捐赠科研通 5166597
什么是DOI,文献DOI怎么找? 2765415
邀请新用户注册赠送积分活动 1747039
关于科研通互助平台的介绍 1635433